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Introduction
Pulmonary arterial hypertension includes a group of dis-
eases characterized by progressive increase in the pulmo-
nary vascular resistance, leading to right ventricular failure 
and premature death. Pulmonary endothelial dysfunction, 
characterized by impaired production of vasodilators and 
over-expression of vasoconstrictors, has been implicated in 
the pathogenesis of the disease.
1)2) Despite intensive efforts, 
the molecular mechanism by which endothelial vasomedia-
tors contribute to pulmonary hypertension, has not been ful-
ly elucidated. Pulmonary vascular remodeling is character-
ized by endothelial cell injury, infiltration of smooth muscle 
cells in the subintima, and thickening of the medial layer in 
proximal vessels.
3) It is usually secondary to the high pulmo-
nary blood flow or pressure, typically seen in various con-
genital heart disease.
4)5) To date, nitric oxide (NO) and endo-
thelin-1 (ET-1) have been identified as major endothelium-
dependent vasomediators. NO is a potent endogenous vaso-
dilator produced in the lung and other tissues by endothelial 
nitric oxide synthase (NOS3).
6) 
Monocrotaline (M) has been reported to injure the endo-
thelium of pulmonary arteries and to induce progressive pul-
monary hypertension in rats, even after a single subcutaneous 
(sc) injection.
7) Simvastatin, is a 3-hydroxyl-3-methylglutaryl 
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ABSTRACT
Background and Objectives: Simvastatin’s properties are suggestive of a potential pathophysiologic role in pulmonary hy-
pertension. The objectives of this study were to investigate changes of pulmonary pathology and gene expressions, including en-
dothelin (ET)-1, endothelin receptor A (ERA), inducible nitric oxide synthase (NOS2), endothelial nitric oxide synthase (NOS3), 
matrix metalloproteinase (MMP) 2, tissue inhibitor of matrix metalloproteinases (TIMP) and caspase 3, and to evaluate the 
effect of simvastatin on monocrotaline (M)-induced pulmonary hypertension. Materials and Methods: Six week old male 
Sprague-Dawley rats were treated, as follows: control group, subcutaneous (sc) injection of saline; M group, sc injection of M 
(60 mg/kg); and simvastatin group, sc injection of M (60 mg/kg) plus 10 mg/kg/day simvastatin orally. Results: On day 28, 
right ventricular hypertrophy (RVH) significantly decreased in the simvastatin group compared to the M group. Similarly, 
right ventricular pressure significantly decreased in the simvastatin group on day 28. From day 7, the ratio of medial thick-
ening of the pulmonary artery was significantly increased in the M group, but there was no significant change in the simvasta-
tin group. The number of muscular pulmonary arterioles was significantly reduced in the simvastatin group. On day 5, gene 
expressions of ET-1, ERA, NOS2, NOS3, MMP and TIMP significantly decreased in the simvastatin group. Conclusion: 
Administration of simvastatin exerted weak inhibitory effects on RVH and on the number of muscular pulmonary arterioles, 
during the development of M-induced pulmonary hypertension in rats. Simvastatin decreased gene expressions on day 5. 
(Korean Circ J 2011;41:518-527)
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coenzyme A reductase inhibitor (HMG CoA inhibitor), and 
is efficacious in both experimental and clinical pulmonary 
hypertension.
8-12) However, in this animal model, the effect 
of simvastatin on M-induced pulmonary hypertension has 
not been established. It has been suggested that simvastatin 
causes endothelial cell apoptosis and attenuates severe pul-
monary hypertension.
13) 
The objectives of this study were to investigate the changes 
produced by simvastatin treatment in pulmonary pathology 
and gene expressions of ET-1, endothelin receptor A (ERA), 
inducible nitric oxide synthase (NOS2), NOS3, matrix metal-
loproteinase (MMP) 2, tissue inhibitor of matrix metallo-
proteinases (TIMP) and caspase-3 genes, in the M-induced 
pulmonary hypertension rat model.
Materials and Methods
Materials
Six-week-old male Sprague-Dawley rats, weighing approx-
imately 250-300 g, were used for this study. All rats were hou-
sed in climate-controlled conditions, with a 12 hours light/12 
hours dark cycle, and had free access to chow and water.
Pulmonary hypertension was induced by the sc injection 
of 60 mg/kg monocrotaline (M) (Sigma Chemicals, St. Louis, 
MO, USA), dissolved in 0.5 N HCl solution. The rats were 
grouped, as follows: control group (n=18), sc injection of sa-
line (0.1 mL/kg); M group (n=36), sc injection of M; simvas-
tatin group (n=36), sc injection of M plus 10 mg/kg/day si-
mvastatin by gavage, during all experimental days. The rats 
were sacrificed after 1 day, 5, 7, 14 and 28 days. Lung tissues 
were removed and immediately frozen at -70°C for enzyme 
analysis, post-fixed in 10% formalin and processed routinely 
for paraffin embedding. All protocols were approved by the 
Institutional Review Board of the School of Medicine of Ewha 
Womans University.
Methods
Organ weights
The rats were weighed and observed for general appear-
ance during the study period. At the scheduled time, the an-
imals were sacrificed and the hearts and lungs were rapidly 
removed. The wet weights of the right ventricle (RV), left 
ventricle and septum (LV+S) were measured, and the ratio 
of organ weight to body weight was calculated. The RV to 
LV+S ratio {RV/(LV+S)} was used as an index of RVH. 
Estimation of mean right ventricular pressure
The animals were placed in the supine position and instru-
mented with an arterial pressure line (Physiological Pressure 
Transducer, MLT1199; AD Instruments, Oxfordshire, UK). 
Hemodynamic parameters were recorded at baseline, and 
after 5, 7, 14 and 28 days. The catheter was placed in the RV to 
estimate the mean right ventricular pressure (RVP). 
Morphometric analysis of the pulmonary arteries
Following gentle perfusion through trachea, the lung tissue 
was fixed with 10% buffered formalin for 24 hours, and then 
embedded in paraffin. Hematoxylin-eosin and Victoria blue 
stains were performed on 3 um-thick sections to evaluate the 
histopathologic changes of pulmonary blood vessels. More 
than 20 images of pulmonary arterioles (25-100 μm diameter) 
per tissue section were captured at a magnification of ×400, 
using the microscopic digital camera, and were analyzed us-
ing an image analysis program (analySIS, Olympus Soft Im-
aging Solutions, Singapore). The external diameter (D) and 
medial thickness on either side (M1 and M2) were measur-
ed along the shortest diameter. The medial wall thickness was 
expressed, as follows: % wall thickness={(M1+M2)/2/D}×100.
The dimension of pulmonary arteries (i.e., the distance be-
tween both sides of the outer elastic layer) and the thickness 
of the medial layer (i.e., the distance between the inner and 
outer elastic layers) were measured. The percent wall thick-
ness of the medial layer of arterioles was determined by di-
viding the medial wall thickness by the dimension. In addi-
tion, the number of pulmonary arterioles accompanied by 
respiratory bronchioles and present in the alveolar wall was 
determined. A total number of 20 randomly selected micro-
scopic fields per tissue section were assessed at a magnifica-
tion ×200.
14)
RNA extraction and cDNA synthesis
Total RNA was extracted by using the TRIzol Reagent
TM 
(Invitrogen, Carlsbad, CA, USA), according to the Trizol me-
thod protocol, and re-suspended in diethyl pyrocarbonate 
water. The final RNA amount was spectrophotometrically de-
termined at 260/280 nm. Quality was assessed as the absence 
of smear of 18 S and 28 S bands, analyzed with Bio analyzer 
2100 (Agilent). RNA samples were stored at -70°C until used. 
cDNAs were synthesized from 1 ug of total RNA, according 
to the manufacture’s protocol (Hight Capacity RNA-to-cD-
NA kit, Appllied Biosystems, USA).
Gene expression analysis by real time reverse 
transcription-polymerase chain reaction
Real-time quantitative polymerase chain reaction (PCR) 
was performed in triplicate in 384-well plates. The 384-well 
high-throughput analysis was performed, using the ABI Pri-
sm 7900 Sequence Detection System Software (Applied Bio-
systems, CA, USA) and white colored 384-well plates (ABgene, 
Hamburg, Germany), for intensification of the fluorescent sig-
nals by a factor of three. The system operates using a thermal 
cycler and a laser that is directed via fiber optics to each of the 
384 sample wells. The fluorescence emission from each sam-520   Gene Expression in Pulmonary Hypertension After Simvastatin Treatment
ple is then collected by a charge-coupled device-camera and 
the quantitative data were analyzed using the Sequence De-
tection System Software (SDS version 2.0, Applied Biosys-
tems, Carlsbad, CA, USA). The reaction mixtures contained 
10 pmol/uL of each primer and 2X SYBR Green PCR Master 
Mix (Applied Biosystems, Carlsbad, CA, USA), which in-
cludes the HotStarTaqt DNA-Polymerase in an optimized buf-
fer, the dNTP mix (with dUTP additive), the SYBRs Green I 
fluorescent dye, and ROX dye as the passive reference. Each 
of the 384-well real-time quantitative PCR plates included 
serial dilutions (1, 1/2 and 1/4) of cDNA, which were used to 
generate relative standard curves for genes.
15)
The resulting first-strand of cDNA was normalized by the 
glyceraldehyde 3-phosphate dehydrogenase gene. The nor-
malized cDNA was the used as a template for the PCR proce-
dure. The specific primers for rat ET-1 were 5’-TCTCGGA 
GAG CAGAGACACA-3’ (forward) and 5’-TGGACTTTG 
GAGTTTCTCCCT-3’ (reverse). The specific primers for 
ERA were 5’-CACAGGCTTCAGTGTGCAT T-3’ (forward) 
and 5’-CAACACAGGCCCTTAGCTTC-3’ (reverse). The 
specific primers for NOS2 were 5’-GGGCCACCTTTATG 
TTTGTG-3’ (forward) and 5’-CCTCAACCTGCTCCTC 
ACTC-3’ (reverse). The specific primers for NOS3 were 5’-CT 
GCGGTGATGTCACTATGG-3’ (forward) and 5’-AAAT 
GTCCTCGTGGTAGGGT-3’ (reverse). The specific primers 
for MMP2 were 5’-AAGAGGCCTGGTTACCCTGT-3’ 
(forward) and 5’-AAGTAGCACCTGGGAGGGAT-3’ (re-
verse). The specific primers for TIMP were 5’-GACCTA 
TAGTGCTGGCTGTG-3’ (forward) and 5’-GATCGCTCT 
GGTAGCCCTTCT-3’ (reverse). And finally, the specific 
primers for caspase 3 were 5’-GAAAGCATCCAGTAGGC-3’ 
(forward) and 5’-TAAGGAAGCCTGGAGCACAG-3’ (re-
verse) (Table 1) (Fig. 1).
All primers were amplified using the same conditions. 
The thermal cycling conditions were 50°C for 2 minutes and 
95°C for 10 minutes, followed by 40 cycles of 95°C for 30 
seconds, 60°C for 30 seconds, and 72°C for 30 seconds. In 
order to exclude the presence of unspecific products, the melt-
ing curve analysis of products was performed routinely after 
finishing amplification by high-resolution data collection, 
during an incremental temperature increase from 60°C to 
95°C, with a ramp rate of 0.21°C/second. We then converted, 
on the basis of the equation, the real-time PCR cycle num-
bers to gene amounts (ng). The real-time PCR analysis was 
performed on an Applied Biosystems Prism 7900 Sequence 
Detection System (PE Applied Biosystems).
16)
Liver enzymes and lipid profiles
Liver enzymes, such as aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT), and lipid profiles, such 
as total cholesterol, triglyceride, high density lipoprotein-
cholesterol (HDL-C), and low density lipoprotein-cholester-
ol (LDL-C), were measured in each group.
Statistical analysis 
Results were expressed as the mean±standard deviation. 
An unpaired two-tailed t-test and the Mann-Whitney test 
were used, and a p<0.05 was considered statistically signifi-
cant. Statistical Package for the Social Sciences (SPSS) for win-
dows version 12.0 (SPSS, Chicago, IL, USA) was used for all 
statistical analyses.
Table 1. Gene sequences of primer of RT-PCR
Gene Forward primer sequences Reverse primer sequences Size
ET-1 TCT CGG AGA GCA GAG ACA CA TGG ACT TTG GAG TTT CTC CCT 156 bp
ERA CAC AGG CTT CAG TGT GCA TT CAA CAC AGG CCC TTA GCT TC 118 bp
NOS2 GGG CCA CCT TTA TGT TTG TG CCT CAA CCT GCT CCT CAC TC 107 bp  
NOS3 CTG CGG TGA TGT CAC TAT GG AAA TGT CCT CGT GGT AGC GT 140 bp
MMP2 AAG AGG CCT GGT TAC CCT GT AAG TAG CAC CTG GGA GGGAT 137 bp
TIMP GAC CTA TAG TGC TGG CTG TG GATC GCT CTG GTA GCC CTT CT 133 bp
Casp3 GAA AGC ATC CAG CAA TAG GC TAAGGA AGC CTG GAG CAC AG 100 bp
RT-PCR: reverse transcription-polymerase chain reaction, ET-1: endothelin-1, ERA: endothelin receptor A, NOS2: inducible nitric oxide 
synthase, NOS3: endothelial nitric oxide synthase, MMP2: matrix metalloproteinase 2, TIMP: tissue inhibitor of matrix metalloproteinases, 
Casp3: Caspase 3
Fig. 1. Typical example of RT-PCR products are shown for the level 
of ET-1, ERA, NOS2, NOS3, MMP 2 and TIMP mRNA measured in 
the lung tissue. The RT-PCR products from the transcripts of ET-1, 
ERA, NOS2, NOS3, MMP2, TIMP, Casp 3 and GAPDH were 156 bp, 
118 bp, 107 bp, 140 bp, 137 bp, 133 bp 100 and 89 bp, respectively. 
ET-1: endothelin-1, ERA: endothelin receptor A, NOS 2: inducible ni-
tric oxide synthase, NOS 3: endothelial nitric oxide synthase, MMP-2: 
matrix metalloproteinase 2, TIMP: tissue inhibitor of matrix metallo-
proteinases, Casp3: caspase 3, GAPDH: glyceraldehyde 3-phos-
phate dehydrogenase.
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Results
Changes of the total body weight and heart weight
From day 5 until day 28, the total weight of the rats decre-
ased significantly in the M group compared with the control 
group. On day 28, the RV weight significantly increased in 
the M group, and significantly decreased in the simvastatin 
group compared with the M group. From day 7, the LV and 
septum weight significantly decreased in the M group and 
there were no significant changes in the simvastatin group. 
On day 28, the RV/LV+S weight ratio significantly decreased 
in the simvastatin group, compared with the M group (Table 2).
Estimation of the right ventricular pressure
From day 5, the mean RVP significantly increased in the M 
group, compared with control group. On day 28, the RVP sig-
nificantly decreased in the simvastatin group compared with 
the M group (Table 3).
Histologic study
The basic pulmonary architecture was similar in each gr-
oup. The predominant changes in the pulmonary vasculature 
occurred in the M group on day 7 and included the develop-
ment of medial thickening in the pulmonary arterioles, com-
pared with both the control group and the simvastatin group 
(Fig. 2).
Morphometric analysis of the pulmonary arteries
The medial wall thickness of the pulmonary artery
In the M group, the ratio of medial thickening to the ex-
ternal diameter of the pulmonary artery significantly incre-
ased from day 7, compared to control. In the simvastatin gr-
oup, the ratio of medial thickening of the pulmonary artery 
was not significantly different from the M group (Table 4).
The number of muscular pulmonary arterioles
The number of muscular pulmonary arterioles significant-
ly increased in the M group, comapared with the C group. 
From day 7, the number of muscular pulmonary arterioles 
significantly decreased in the simvastatin group, compared to 
the M group (Table 5).
Gene expressions in rat lung tissues
Gene expressions of endothelin-1
On days 5 and 7, in the M group, the expression of gene ET-1 
was higher than in the control group. On day 5, in the Simvas-
tatin group, the same gene was lower expressed than in the M 
group (Fig. 3).
Gene expressions of endothelin receptor A 
On day 1, the ERA gene was more expressed in the M gr-
Table 2. Changes in the whole body weight, right ventricle weight, and left ventricle and septum weight, measured in each group on day 1, 5, 
7, 14 and 28
Group/Day Total weight (g) RV (g) LV+S (g) RV/LV+S
C 01
05
07
14
28
284.8±15.2
342.0±46.0
356.5±12.8
403.2±22.4
436.0±19.7
0.18±0.02
0.22±0.01
0.24±0.02
0.26±0.02
0.25±0.02
0.69±0.09
0.71±0.05
0.78±0.05
0.82±0.05
0.88±0.06
0.26±0.06
0.31±0.03
0.30±0.02
0.30±0.02
0.32±0.03
M 01
05
07
14
28
280.6±10.0
288.8±12.7*
297.6±18.8*
336.1±14.8*
335.7±41.3*
0.20±0.02
0.23±0.03
0.22±0.03
0.30±0.03
0.59±0.02*
0.60±0.11
0.69±0.09
0.62±0.09*
0.73±0.03*
0.71±0.09*
0.33±0.05
0.33±0.03
0.33±0.03
0.41±0.02
0.83±0.04
S  01
05
07
14
28
280.0±12.1
300.2±16.1
303.3±18.9
351.3±8.1
349.0±16.7
0.20±0.02
0.22±0.03
0.21±0.02
0.32±0.03
0.53±0.03†
0.64±0.07
0.64±0.07
0.71±0.14
0.77±0.06
0.78±0.09
0.31±0.02
0.37±0.04
0.29±0.03
0.41±0.02
0.67±0.03†
*p<0.05 vs. the corresponding value in the C group, †p<0.05 vs. the corresponding value in the M group. C: control, M: monocrotalin, S: sim-
vastatin, RV: right ventricle, S; septum, LV: left ventricle
Table 3. Right ventricular pressure in each group (mmHg)
Days C group M group S group
01 12.3±3.5 14.1±2.5 17.0±1.1
05 11.6±2.4 17.3±5.3* 15.0±2.1
07 10.2±3.1 15.4±3.5* 17.0±2.1
14 13.2±3.2 22.6±2.9* 24.0±1.4
28 12.5±1.9 30.3±2.8* 13.7±2.6†
*p<0.05 vs. the corresponding value in the C group, †p<0.05 vs. the 
corresponding value in the M group. C: control, M: monocrotaline, 
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oup than in control group. On day 5, however, expression of 
the same gene significantly decreased in the simvastatin gr-
oup, compared with the M group (Fig. 4). 
Gene expressions of inducible nitric oxide synthase
On day 7, expression of NOS2 significantly increased in the 
M group compared to control group. On day 5, NOS2 was 
less expressed in the simvastatin group than in the M group 
(Fig. 5).
Gene expressions of endothelial nitric oxide synthase
On days 5 and 7, expression of NOS3 significantly incre-
ased in the M group compared to control group. On day 5, 
NOS3 was less expressed in the simvastatin group than in 
the M group (Fig. 6).
Gene expressions of matrix metalloproteinases
On days 1 and 28, expression of MMP2 significantly in-
creased in the M group compared to control group. On day 5, 
MMP2 was less expressed in the simvastatin group than in 
the M group (Fig. 7).
Gene expressions of tissue inhibitor of matrix 
metalloproteinases
On days 5, 14 and 28, expression of TIMP significantly in-
creased in the M group compared to control group. On day 5, 
TIMP was less expressed in the simvastatin group than in 
the M group (Fig. 8).
Gene expressions of caspase 3
On day 5, expression of caspase 3 significantly decreased in 
the simvastatin group, compared to the M group (Fig. 9).
Liver enzymes and serum lipid profiles 
On day 5, ALT significantly increased in the M group com-
pared to control group. In contrast, on days 5 and 7, triglycer-
ide significantly decreased in the M group compared to con-
trol group.
On days 1 and 7, triglyceride also significantly decreased in 
the simvastatin group compared to the M group. On day 14, 
HDL-C significantly decreased in the M group compared to 
control group. LDL-C, AST and total cholesterol showed no 
significant changes after either M or simvastatin treatment 
(Table 6).
 
Discussion
We confirmed that pulmonary hypertension was induced 
by M, as evidenced by pathologic finding and gene expres-
sions. The evidence includes; first, a progressive increase in 
the ratio of RV to LV+S was significantly noted in both our 
previous study
14-16) and in the present study. Second, the RVP 
progressively increased in the M group, compared with the 
control group. Third, in the M group, predominant changes 
in the pulmonary vasculature included the development of 
medial thickening in the pulmonary arterioles and increased 
number of intra-acinar muscular arteries. Fourth, the expres-
Fig. 2. Photographs of pulmonary arterioles in the three investigated groups (Victoria blue stain ×400). A: the muscular layer of pulmonary arterioles 
was normal in C group. B: the medial layer of pulmonary arterioles was progressively thickened after M injection in M group. C: the medial wall 
thickness after M injection was significantly attenuated in the simvastatin group. C: control group, M: monocrotaline group, S: simvastatin group.
C group M group S group A   B   C  
Table 4. Ratio of the medial thickening of pulmonary artery in each 
group (%)
Day C group M group S group
01 9.2±0.7 08.2±0.8 08.6±0.6
05 7.8±0.9 09.0±0.9 10.6±1.3
07 9.4±1.1 13.8±1.7* 12.4±2.1
14 7.8±0.8 20.1±3.6* 19.8±1.9
28 7.6±0.8 23.8±2.5* 22.6±2.7
*p<0.05 vs. the corresponding value in the C group. C: control, M: 
monocrotaline, S: simvastatin
Table 5. Number of muscular pulmonary arterioles in each group
Day C group M group S group
01 2.3±0.1 2.4±0.1 2.3±0.2 
05 2.3±0.1 2.5±0.1 2.1±0.0
07 2.4±0.1 3.1±0.1* 2.2±0.2†
14 2.4±0.1 3.4±0.4* 2.8±0.1†
28 2.4±0.3 5.7±0.6* 4.9±0.3†
*p<0.05 vs. the corresponding value in the C group, †p<0.05 vs. the 
corresponding value in the M group. C: control, M: monocrotaline, 
S: simvastatinYun Hee Lee, et al.   523
sions of ET-1, ERA, NOS2, NOS3, MMP and TIMP genes were 
significantly increased in the M group. These pathologic find-
ings were consistent with other results demonstrating a sig-
nificant rise in pulmonary blood pressure and apparent RVH 
after M injection in the rat model.
17)18) 
During the development of M-induced pulmonary hyper-
tension in rats, administration of simvastatin exerted inhibi-
tory effects on RVH and on a number of muscular pulmo-
nary arterioles. On day 28, RVH significantly decreased in the 
simvastatin group compared to the M group. Starting with 
the first week, the number of muscular pulmonary arterioles 
was significantly reduced in the simvastatin group, com-
pared to M group. However, the ratio of medial thickening 
of the pulmonary artery has not changed significantly in the 
simvastatin group. On day 5, expressions of ET-1, ERA, NOS2, 
NOS3, MMP and TIMP genes significantly decreased in the 
Fig. 3. Gene expressions of endothelin-1 in the lungs, determined at day 1, day 5, 1 week, 2 weeks and 4 weeks after simvastatin treatment. 
*p<0.05 vs. the corresponding value in the C group, †p<0.05 vs. the corresponding value in the M group. C: control, M: monocrotaline, S: 
simvastatin.
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Fig. 4. Gene expressions of endothelin receptor A in the lungs, determined at day 1, day 5, 1 week, 2 weeks and 4 weeks after simvastatin treat-
ment. *p<0.05 vs. the corresponding value in the C group, †p<0.05 vs. the corresponding value in the M group. C: control, M: monocrotaline, S: 
simvastatin. 
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Fig. 5. Gene expressions of inducible nitric oxide synthase in the lungs, determined at day 1, day 5, 1 week, 2 weeks and 4 weeks after simvas-
tatin treatment. *p<0.05 vs. the corresponding value in the C group, †p<0.05 vs. the corresponding value in the M group. C: control, M: monocro-
taline, S: simvastatin. 
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simvastatin group. 
Statins, such as 3-hydroxyl-3-methylglutaryl (HMG)-CoA 
reductase inhibitors, have been developed as lipid-lowering 
drugs. In addition, recent experiments and clinical trials have 
demonstrated that statins also exert vasculoprotective effects, 
independent of their cholesterol-lowering effects.
19) Thus, 
recent studies have suggested that statins may have potential 
use in the treatment of pulmonary hypertension.
8)9)
However, there is still controversy on the effect of simvas-
tatin on pulmonary hypertension. Simvastatin attenuates ne-
ointimal thickening of the smooth muscle.
10) Simvastatin is 
effective in inducing apoptosis in hyperproliperative pulmo-
nary vascular lesions and could be considered as a potential 
drug for treatment of human severe pulmonary hypertension. 
Fig. 6. Gene expressions of endothelial nitric oxide synthase mRNA in the lungs, determined at day 1, day 5, 1 week, 2 weeks and 4 weeks after 
simvastatin treatment. *p<0.05 vs. the corresponding value in the C group, †p<0.05 vs. the corresponding value in the M group. C: control, M: 
monocrotaline, S: simvastatin.
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Fig. 7. Gene expressions of matrix metalloproteinase 2 in the lungs, determined at day 1, day 5, 1 week, 2 weeks and 4 weeks after simvastatin treat-
ment. *p<0.05 vs. the corresponding value in the C group, †p<0.05 vs. the corresponding value in the M group. C: control, M: monocrotaline, S: simv-
astatin.
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Fig. 8. Gene expressions of tissue inhibitor of matrix metalloproteinases in the lungs, determined at day 1, day 5, 1 week, 2 weeks and 4 weeks after 
simvastatin treatment. *p<0.05 vs. the corresponding value in the C group, †p<0.05 vs. the corresponding value in the M group. C: control, M: monocro-
taline, S: simvastatin.
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Nishimura et al.
10) demonstrated impressive hemodynamic 
responses to simvastatin therapy, and also suggested that sim-
vastatin promotes apoptosis of the smooth muscle cells in pul-
monary arterioles. That data
10) demonstrated the down-regul-
ation of the inflammatory genes such as fos, jun, and TNF-a 
and the up-regulation of the cell cycle inhibitor p27Kip1, the 
NOS3 gene, and the bone morphogenetic protein receptor 
type 1. In contrast, our experiments demonstrated a significant 
down-regulation of NOS3 expression in simvastatin treated 
animals, suggesting that any increase in NO by simvastatin 
would relate to increased bioavailability, rather than enzyme 
expression.
However, McMurtry et al.
11) reported no effect of simvasta-
tin on pulmonary hypertension, i.e., simvastatin could not re-
verse the M-induced pulmonary arterial hypertension. In that 
study, simvastatin improved echocardiographic parameters 
of pulmonary hypertension, including the pulmonary artery 
acceleration time and the RV thickness after 1-2 weeks, but 
the effect was not sustained, and ultimately, rats treated with 
simvastatin developed severe pulmonary arterial hyperten-
sion and expired. Our study revealed a weak inhibitory ef-
fect of simvastatin on RVH and pulmonary hypertension. In 
our model, treatment with simvastatin initially appeared to im-
prove lung pathologic findings, but did not reverse the M-
induced pulmonary hypertension. In general the simvastatin 
effect of attenuation of RVH and pulmonary hypertension 
seems to be weaker than that of bosentan.
14)
NO is best known for its marked vasodilator activity. Ex-
ogenous NO is useful in the clinical management of acute 
pulmonary hypertensive crisis. However, NO is also a reac-
tive radical capable of tissue injury, either directly or after re-
acting with other radicals. For example, an extremely fast re-
action of NO with superoxide yields the highly cytotoxic pe-
roxynitrite.
20) There are three subtypes of NOS {i.e., NOS2, 
NOS3 and neuronal NOS (nNOS)}. The NO can contribute 
to oxidative stress and, in association with tissue injury, NOS2 
Fig. 9. Gene expressions of caspase 3 in the lungs, determined at day 1, day 5, 1 week, 2 weeks and 4 weeks after simvastatin treatment. †p<0.05 
vs. the corresponding value in the M group. C: control, M: monocrotaline, S: simvastatin. 
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Table 6. Liver enzymes and lipid profiles in each group (mg/dL)
Group AST  ALT TC TG HDL-C LDL-C
C 01d
05d
07d
14d
28d
118.7±22.5
134.3±10.0
126.7±18.4
111.0±7.2
159.0±16.7
040.0±7.2
032.7±2.1
036.7±3.1
034.0±2.6
037.7±3.5
51.0±12.3
52.3±9.3
58.7±4.0
50.3±4.9
43.0±6.1
086.3±19.1
122.3±10.5
145.7±49.7
155.7±11.6
043.7±15.3
26.0±5.6
23.0±4.4
26.7±2.3
24.7±0.6
17.7±1.5
6.3±1.5
7.7±2.1
7.7±1.2
6.0±1.0
4.7±2.3
M 01d
05d
07d
14d
 28d
105.5±15.1
122.0±30.5
154.3±33.3
127.8±15.9
115.0±52.6
039.0±8.5
040.7±5.5*
044.7±6.1
035.8±5.1
058.7±38.9
56.3±9.6
52.7±9.9
53.5±8.8
50.8±8.0
48.0±10.6
122.7±37.7
059.8±13.7*
053.7±25.6*
109.2±53.8
039.0±21.7
26.3±5.2
21.5±3.6
23.0±3.9
22.0±1.7*
15.0±2.9
8.7±2.0
7.8±1.9
9.7±2.3
7.7±2.9
9.8±2.4
S 01d
 05d
 07d
 14d
 28d
113.0±21.8
115.2±16.7
126.0±32.9
110.3±19.7
183.3±137.3
041.2±10.5
042.7±9.3
047.7±23.2
034.3±2.3
123.1±201.2
48.4±6.4
50.2±4.7
64.3±12.2
51.2±5.2
52.1±15.5
057.4±29.4†
055.7±19.4
054.7±16.4†
076.7±33.2
053.4±35.4
23.0±2.7
22.0±1.4
24.0±1.7
21.7±2.1
17.0±4.5
6.4±1.5
9.2±2.3
14.0±7.8
8.3±1.2
9.5±2.6
*p<0.05 vs. the corresponding value in the control group, †p<0.05 vs. the corresponding value in the M group. C: control, M: monocrotalin, S: 
simvastatin, AST: aspartate aminotransterase, ALT: alanine aminotransferase, TC: total cholesterol, TG: triglyceride, HDL-C: high density li-
poprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol526   Gene Expression in Pulmonary Hypertension After Simvastatin Treatment
is often up-regulated. Transient NOS2 induction in the pul-
monary vascular wall at the beginning of chronic hypoxia 
participates in the pathogenesis of pulmonary hypertension. 
In our study, on day 7, NOS2 significantly increased in the M 
group compared to control and significantly decreased in the 
simvastatin group, compared to the M group, on day 5. In chro-
nic hypoxia, many authors have reported elevated NOS mRNA 
and protein in both the lungs and the pulmonary vessels.
21) 
However, most of those studies either focused on NOS3 or did 
not discriminate between various NOS isoforms. In a study 
comparing NOS3, nNOS and NOS2 activity in mice, NOS3 
showed the most important role in regulating pulmonary 
circulation.
22) Similarly, the endothelial NO production has 
been shown to play a key role in vascular reactivity and in 
the modulation of smooth muscle cell proliferation, as well as 
inflammation.
21) Therefore, at least, in part, the protective ef-
fects of statins on the endothelium may contribute to recov-
er pulmonary hypertension. In our study, NOS3 has not in-
creased significantly in the simvastatin group.
Li et al.
23) investigated the hypothesis that statins regulate 
vascular remodeling by modulation of MMP secretion in pri-
mary cultured pulmonary artery smooth muscle cells. Thus, 
angiotension II induced a concentration-dependent MMP2 
secretion. Pre-exposure of cells to simvastatin blocked the an-
giotension II-stimulated MMP2 release. Simvastatin suppress-
ed ET-1-induced MMP2 release through the Rho/ROCK pa-
thway. In contrast, there was no effect of angiotensin II on the 
expression of TIMP genes. These results indicated a novel 
statins-regulation of Rho/ROCK signaling against pulmo-
nary vascular remodeling, and suggested that statins could 
prove usefulness in targeting this pathway in pulmonary hy-
pertension and other disease conditions.
24) 
In rats, during treatment of severe pulmonary hypertension 
with a HMG-CoA reductase inhibitor, simvastatin caused ap-
optosis of the lumen-obliteration cells, which was associated 
with significant reduction of pulmonary artery pressure and 
of RVH.
13) In normal rat lungs, blood vessels are negative for 
caspase 3 staining. Simvastatin treatment causes activation of 
caspase-3 and significantly decreases the number of pulmo-
nary vascular lesions. Treatment with simvastatin induced ap-
optosis of endothelial cells in obliterated vessels. Simvastatin 
reduced pulmonary hypertension through apoptosis-induc-
ed reopening of the occluded vessels, as shown by caspase-3 
immunohistochemistry.
13) It is now becoming clear that st-
atins can trigger apoptosis using both caspase-dependent and 
caspase-independent Rho kinase-dependent pathways.
25) 
The ability of HMG-CoA reductase inhibitors to induce ap-
optosis was demonstrated in both rat pulmonary vein endo-
thelial cells
26) and human hepatocytes.
27) In our study, the si-
mvastatin effect on caspase-3 mRNA was not apparent, suggest-
ing that more study on high dose simvastatin treatment is 
needed. 
Simvastatin has both anti-proliferative and pro-apoptotic 
effects on vascular smooth muscle cells and enhances the 
endothelial production of NO. Simvastatin stabilizes the en-
dothelial barrier function and promotes anti-inflammatory 
effect, which leads to atherogenesis.
The dose of simvastatin, used both experimentally and cli-
nically, was inconsistent among the various other investiga-
tors. Girgis et al.
24) used 20 mg/kg/day of simvastatin and fo-
und that simvastatin attenuated and induced regression of 
chronic hypoxic pulmonary hypertension. Wilkins et al.
28) 
gave the patients 80 mg/day of simvastatin for 6 months, and 
found that, when added to conventional therapy in patients 
with pulmonary arterial hypertension, simvastatin produced 
a small and transient early reduction in both the RV mass 
and the N terminal pro B type natriuretic peptide (NT-pro-
BNP) level. Liu et al.
29) used 2 mg/kg/d of simvastatin for 35 
days in rats, and resulted in prevention of pulmonary hyper-
tension. However, in McMurtry’s rat study,
11) the same dose 
of 2 mg/kg/d of simvastatin did not reverse the M-induced 
pulmonary arterial hypertension. 
In conclusion, treatment of simvastatin in M-induced hy-
pertensive rats blunted the development of M-induced pul-
monary hypertension and resulted in a weak attenuation of 
both RVH and vascular remodeling. Our results in M-in-
duced pulmonary hypertension suggest that all seven genes 
increased, and all of those increases may play a role in RVH 
and remodeling. The sensitive markers of decreased expres-
sion of ERA and NOS2 genes appeared earlier than other 
pathologic findings. Also, the decreased gene expression of 
MMP2 could be a marker of pulmonary hypertension treat-
ment. Further studies are in progress to determine the effects 
of simvastatin on other gene expressions in the M-induced 
pulmonary hypertension rat model. 
Larger sample sizes are needed to measure hemodynamics 
and follow-ups should extend for more than 4 weeks. The 
follow up duration is a critical factor to evaluate the effecti-
veness of the simvastatin treatment on M-induced pulmona-
ry hypertension. Finally, further studies are necessary to ex-
plore the intricate mechanisms of simvastatin treatment in 
M-induced pulmonary hypertension.
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